Propanc Health Group Corp (OTCMKTS:PPCH) Making A Comeback

Propanc Health Group Corp (OTCMKTS:PPCH) is making a comeback after announcing results from recent studies for its lead product, PRP. PRP, is a once-daily pro-enzyme treatment as a clinically proven therapeutic option in the treatment and prevention of cancer. PRP would be the first therapy of its kind, as there are no FDA approved therapies used for the long-term prevention or management of these conditions.Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. PPCH has developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Its products involve or employ proenzymes, which are inactive precursors of enzymes.The latest data confirmed a synergistic response to a broad range of cancer indications, which also includes kidney, melanoma, brain, prostate, liver, uterine and lung cancers. The data provided compelling evidence that PRP has the potential to fight a broad range of cancer types, some with high unmet medical needs, which the company will look towards investigating through clinical trials. Furthermore, data from the recent cell line studies tested at the R&D facility of its contract research partner, vivoPharm LLC, in Hershey, PA, showed a synergistic response between the two active components, trypsinogen and chymotrypsinogen, further strengthening its lead patent claims in key jurisdictions such as North America and Europe. Dr. Julian Kenyon, Propanc's Chief Scientific Officer said:

"I have no doubt PRP represents a new therapeutic drug class with significant potential across a broad range of cancers. Confirming the significant synergistic response to the majority of solid tumors tested which further strengthens our patent claims is very important. This agrees with my previous experience with proenzyme treatment in the clinic, where I observed a number of terminally ill patients suffering from a broad range of cancers survive significantly longer than anticipated, free from any severe, or even serious side effects. I look forward to progressing PRP to additional human studies as soon as possible."

PPCH also is making progress in the United Kingdom. Propanc will be meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA) UK at the end of April. At this meeting, Propanc will discuss the company's ongoing development activities for PRP, including preparation and structure of animal safety/toxicology studies and its proposed early stage patient trials, together with supporting activities. Later this year, PPCH will submit a clinical trial application in the UK initially targeting patients with advanced solid tumors in Phase I, followed by pancreatic and ovarian cancer indications in Phase II trials. Both these lead indications qualify for orphan drug designation, which the company intends to prepare and apply for after its meeting with the MHRA.Last month, Propanc filed a third patent regarding the use of its lead product, PRP, as a method to treat cancer by targeting cancer stem cell eradication, whilst sparing normal stem cells. Through the company's research partners at the Universities of Jaén and Granada in Spain, experiments were conducted using isolated cancer stem cells (CSCs) from patients, comparing the behavior of these cells pre and post treatment with PRP by examining the genetic pathways that control these cells. The results could not have been more convincing.Shares have been on a downtrend for all of last year and the better part of this year on the back of toxic financings that have diluted shareholders. PPCH negotiated a $4 million toxic deal with MG Partners II Limited, an affiliate of Magna Corp. Magna is perhaps the biggest toxic funder in penny stock land. The conversion price for the initial $1.2 million is $.0346. Since we are below that price, “the Note shall be convertible at a price per share that is equal to a twenty percent (20%) discount to the average of the two (2) lowest closing prices of the common stock on the Maker’s then current trading market in the five (5) trading days prior to the date of conversion.”The latest news from PPCH is indeed positive and explains why the stock bounced. We think if the company can make further advances, it can overcome Magna's selling. However, it won't be easy. The company really needs to deliver and bring in new buyers and get the shorts covering. In the end, regardless of the deal with Magna, it all comes down to the science. If the science is proven, PPCH will not only bounce, but shares are off to the races. We will be updating Insider Financial as soon as we know more. For continuing coverage on PPCH and our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in PPCH and have not been compensated for this article.